Overview

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

Status:
Completed
Trial end date:
2006-10-26
Target enrollment:
Participant gender:
Summary
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fondaparinux
PENTA